Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564307 | 0.81 | CLK4 (0.53) | CLK4KDM1AGABRG2GABRB3GABRA5 | |
| SCHEMBL5563717 | 0.78 | KDM1A (0.43) | CLK4KDM1AGABRG2GABRB3GABRA5 | |
| SCHEMBL23601916 | 0.77 | NOTUM (0.44) | KDM1AIDO1MAP4K4 | |
| SCHEMBL20923972 | 0.77 | HSD17B1 (0.63) | KDM1ACYP1A2CYP2C19 | |
| SCHEMBL2695324 | 0.76 | USP30 (0.47) | USP30 | |
| SCHEMBL5559799 | 0.75 | CLK4 (0.50) | CLK4KDM1AGABRG2GABRB3GABRA5 | |
| SCHEMBL20019516 | 0.75 | KDM1A (0.70) | CLK4KDM1AGABRG2GABRB3GABRA5 | |
| SCHEMBL3266198 | 0.75 | CLK4 (0.53) | CLK4GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL5562910 | 0.75 | MAP4K4 (0.62) | CLK4GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4021783 | 0.75 | CYP11B2 (0.56) | CLK4GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100497333-C | Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders | HOFFMANN LA ROCHE (CH) | 2009-06-10 | — | — | CN | disclosed |
| EP-1474416-B1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| EP-1651234-B1 | COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-7235547-B2 | Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist | HOFFMANN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1651234-A1 | COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-03 | — | — | EP | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| CN-1633430-A | Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders | HOFFMANN LA ROCHE (CH) | 2005-06-29 | — | — | CN | disclosed |
| US-20050049243-A1 | Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist | HOFFMANN-LA ROCHE INC. | 2005-03-03 | — | — | US | disclosed |
| WO-2005014002-A1 | COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| EP-1474416-A1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
| WO-2003066623-A1 | DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049243-A1 | Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist | GRM2, GRIK2, GRIA2 | CLK4 3412/4885KDM1A 351/4885GABRG2 533/4885 |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | CYP1B1, GRIN2B, CYP4B1 | CLK4 4289/4885KDM1A 513/4885GABRG2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.